Amisulpride: A safe and effective option for the long-term treatment of patients with schizophrenia

被引:1
作者
Naber, D [1 ]
Arlt, J [1 ]
Lambert, M [1 ]
机构
[1] Univ Hamburg, Dept Psychiat, D-20246 Hamburg, Germany
关键词
amisulpride; atypical antipsychotic; long-term treatment; schizophrenia;
D O I
10.1080/13651500310001545
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Long-term treatment of patients with schizophrenia is particularly difficult. An advantageous efficacy/safety profile of the selected antipsychotic is particularly important during this phase, as an insufficient response or poorly tolerated side-effects are likely to reduce compliance, notoriously poor in chronic schizophrenia patients. The atypical antipsychotic amisulpride has demonstrated good efficacy against both the positive and negative symptoms of schizophrenia in long-term clinical trials. Three studies involved treatment with amisulpride for 12 months, one in patients with positive or mixed symptoms and two in patients with predominantly negative symptoms. A further two studies, both involving patients with positive or mixed symptoms, evaluated amisulpride over periods of up to 6 months. In the three 12-month studies, amisulpride was significantly more effective than haloperidol against positive symptoms and showed a trend towards greater improvement in negative symptoms; significantly better effects compared with placebo were also seen in patients with predominantly negative symptoms. Amisulpride was well tolerated with low drop-out rates compared to standard treatment, indicating good compliance.
引用
收藏
页码:167 / 175
页数:9
相关论文
共 50 条
[31]   Paliperidone extended-release in the short- and long-term treatment of schizophrenia [J].
Valsecchi, Paolo ;
Garozzo, Andrea ;
Nibbio, Gabriele ;
Barlati, Stefano ;
Deste, Giacomo ;
Turrina, Cesare ;
Sacchetti, Emilio ;
Vita, Antonio .
RIVISTA DI PSICHIATRIA, 2019, 54 (02) :43-58
[32]   Altered cerebellar effective connectivity in first-episode schizophrenia and long-term changes after treatment [J].
Wei, Xia ;
Cao, Hengyi ;
Luo, Chunyan ;
Zhao, Qiannan ;
Xia, Chao ;
Li, Ziyu ;
Liu, Zhiqin ;
Zhang, Wenjing ;
Gong, Qiyong ;
Lui, Su .
PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2024, 78 (10) :605-611
[33]   The long term treatment of schizophrenia: effect on patients lives [J].
Jonathan Hellewell .
Annals of General Psychiatry, 5 (Suppl 1)
[34]   Long-term studies of antipsychotic drugs in schizophrenia [J].
Lewander, T .
EUROPEAN PSYCHIATRY, 1996, 11 (03) :127-134
[35]   Neuroleptic malignant syndrome without fever after addition of oxcarbazepine to long-term treatment with amisulpride [J].
Angelopoulos, Petros ;
Markopoulou, Maria ;
Kyamidis, Kyriakos ;
Bobotas, Konstantinos .
GENERAL HOSPITAL PSYCHIATRY, 2008, 30 (05) :482-484
[36]   Safety profile of amisulpride in short- and long-term use [J].
Rein, W ;
Coulouvrat, C ;
Dondey-Nouvel, L .
ACTA PSYCHIATRICA SCANDINAVICA, 2000, 101 :23-27
[37]   Treatment Compliance in the Long-Term Paranoid Schizophrenia Telemedicine Study [J].
Krzystanek M. ;
Krysta K. ;
Skałacka K. .
Journal of Technology in Behavioral Science, 2017, 2 (2) :84-87
[38]   TREATMENT PROGRAM AND LONG-TERM OUTCOME IN CHRONIC-SCHIZOPHRENIA [J].
KANE, JM .
ACTA PSYCHIATRICA SCANDINAVICA, 1990, 82 :151-157
[39]   French Expert Consensus Guidelines for long-term treatment in schizophrenia [J].
Vanelle, JM .
ANNALES MEDICO-PSYCHOLOGIQUES, 2005, 163 (09) :758-763
[40]   Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia [J].
Kasper, S ;
Lerman, MN ;
McQuade, RD ;
Saha, A ;
Carson, WH ;
Ali, M ;
Archibald, D ;
Ingenito, G ;
Marcus, R ;
Pigott, T .
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2003, 6 (04) :325-337